Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals (NASDAQ:AGIO) in a research note published on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts also recently issued reports on AGIO. Oppenheimer reiterated a buy rating and issued a $83.00 target price on shares of Agios Pharmaceuticals in a research note on Monday. Cann reiterated a buy rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. Finally, SunTrust Banks reiterated a buy rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agios Pharmaceuticals has an average rating of Buy and a consensus price target of $75.70.

Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $5.34 during midday trading on Tuesday, hitting $56.08. The stock had a trading volume of 571,900 shares, compared to its average volume of 510,360. Agios Pharmaceuticals has a 12 month low of $39.24 and a 12 month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The company had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the company earned ($1.63) EPS. sell-side analysts expect that Agios Pharmaceuticals will post -6.59 earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $67.12, for a total transaction of $2,349,200.00. Following the completion of the sale, the chief executive officer now directly owns 35,000 shares in the company, valued at $2,349,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $71.09, for a total transaction of $71,090.00. Following the sale, the director now owns 84,394 shares of the company’s stock, valued at $5,999,569.46. The disclosure for this sale can be found here. Insiders have sold 166,746 shares of company stock valued at $11,344,756 over the last 90 days. Company insiders own 5.43% of the company’s stock.

A number of hedge funds have recently modified their holdings of AGIO. QS Investors LLC acquired a new stake in Agios Pharmaceuticals during the second quarter worth approximately $144,000. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares in the last quarter. Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at approximately $206,000. Teacher Retirement System of Texas acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $225,000. Finally, S&CO Inc. acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at approximately $227,000. Hedge funds and other institutional investors own 94.38% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/agios-pharmaceuticals-agio-given-a-90-00-price-target-by-canaccord-genuity-analysts/1761344.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.